Skip to main content
. 2023 May;385(2):106–116. doi: 10.1124/jpet.122.001431

Fig. 1.

Fig. 1.

PK analysis of selumetinib and the SOS1 inhibitor BI-3406. (A) and (B). Plasma concentrations (nM) of selumetinib (10 mg/kg) and BI-3406 (50 mg/kg) were measured over 10 hours. Two doses were separated by 6 hours. The first PK measurement was at 15 minutes. After the first dose, a second dose was administered at 6 hours. Plasma concentration of 10 mg/kg selumetinib (left panels) and 50 mg/kg BI-3406 (right panels) in non–tumor-bearing mice [e.g., wild-type littermates of tumor-bearing mice with genotypes Nf1fl/fl or Nf1fl/+ (A)] and tumor-bearing mice (B). Plasma concentrations of 10 mg/kg selumetinib (C) and 50 mg/kg BI-3406 (D) compared from three experiments: tumor-bearing mice, non–tumor-bearing mice, and after 2 months of dosing, each using selumetinib at the designated concentration of 5 or 10 mg/kg, each at 4 hours after a final dose of designated drugs.